Biodel (BIOD) Posts Q4 Loss of 5c/Share; Will Explore Strategic Alternatives

Biodel (NASDAQ: BIOD) reported Q4 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11).

Additionally, the Company announced that its Board of Directors has approved a plan to explore strategic alternatives to further realize value from its pipeline assets and to preserve the Company's significant cash balance. As part of this plan, enrollment in BIOD-531 Study 3-157 is being suspended and the Company will retain an advisor to assist in this process of evaluating its strategic alternatives.

For earnings history and earnings-related data on Biodel (BIOD) click here.

You May Also Be Interested In

• S&P 500 may pull back before midterms, but Citi says buy the dip
• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Vireo Growth completes acquisition of C21 Investments